Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Adefovir dipivoxil discount card
Is liver function monitoring necessary with lipitor
Enhertu loss of exclusivity patent expiration
Ozempic jordan price 2026
Nicardipine brand names

Tafamidis generic?

See the DrugPatentWatch profile for Tafamidis

Tafamidis is a transthyretin (TTR) stabilizer used primarily to treat transthyretin amyloid cardiomyopathy (ATTR‑CM) and, more recently, hereditary transthyretin amyloidosis (hATTR) that affects the peripheral nerves and autonomic system.
The FDA‑approved brand name is Ivadien (also known as Vyndaqel in the EU), but it is a “biologic‑type” small‑molecule drug with a relatively short patent life, so a generic version is expected to reach the market once the original patents expire or if a generic entrant files a successful Abbreviated New Drug Application (ANDA).

1. Current Generic Status (2024)

Region Generic Availability Notes
United States Not yet approved The U.S. patents covering tafamidis (including formulation and method of use) are still in force; the FDA has not yet cleared a generic version. A generic entrant would need to file a new ANDA and demonstrate bioequivalence.
European Union Available A generic tafamidis (same active ingredient, same dosage forms) was launched in the EU after the expiry of the original patents. It is marketed under a generic brand name (often “tafamidis” or “tafamidis‑S” by various manufacturers).
Canada Available Generic tafamidis is marketed by several Canadian generic drug manufacturers.
Australia Available Generic tafamidis is listed on the Australian Pharmaceutical Benefits Scheme (PBS) with a generic brand name.
Other countries Variable Many other markets have generics, depending on local patent status and regulatory approvals.

Bottom line: If you’re in the U.S., you’ll still be purchasing the brand‑name Ivadien (or its equivalents) until the FDA approves a generic. In the EU, Canada, Australia, and most other countries, a generic form is already on the market.

2. What the Generic Should Look Like

  • Dose forms: 20 mg tablets (the standard dose for ATTR‑CM) and 40 mg tablets (for hATTR in adults).
  • Strengths: 20 mg is the most common; higher doses (40 mg) are used in some hATTR cases.
  • Dosage regimen: Typically one tablet daily, taken with a meal for optimal absorption.
  • Bioequivalence: Generic manufacturers must match the brand‑name formulation in terms of pharmacokinetics (AUC, Cmax) within the FDA’s 90 % confidence interval limits of 80‑125 %.
  • Labeling: Should include the same indications, warnings, dosage instructions, and pharmacology information.

3. How Generics Get Approved

  1. Patent expiry or litigation outcome – The original patents must either expire or be invalidated.
  2. ANDA filing – A generic manufacturer submits an ANDA to the FDA, including chemistry, manufacturing, and control (CMC) data, bioequivalence studies, and labeling.
  3. FDA review – If the bioequivalence data meet the criteria, the FDA clears the generic for marketing.
  4. Post‑marketing surveillance – Once on the market, the generic is monitored for safety and efficacy.

4. Practical Tips if You’re Looking to Get Tafamidis

Situation What to do
You live in the U.S. Keep an eye on the FDA’s drug approvals database. If a generic enters the market, the price could drop significantly (generics often cost 10‑30 % of the brand price).
You’re in the EU/Canada/Australia Contact your pharmacy; generic tafamidis is usually cheaper than the brand. Verify the manufacturer’s quality (look for GMP certification).
You’re a clinician When prescribing, you can request the generic if available, but ensure you’re compliant with local prescribing guidelines (some jurisdictions require the brand for certain reimbursement categories).
You’re a patient Check with your insurer or provincial drug plan to see if the generic is covered. Many plans now cover the generic automatically once it’s available.

5. Common FAQs

FAQ Answer
Will the generic have the same side‑effect profile? Yes – the active ingredient and its pharmacodynamics are identical. Some generics may differ in inactive excipients, but these usually do not affect efficacy.
Can I switch from brand to generic mid‑treatment? Yes, but discuss with your prescriber. Switching is generally safe because the bioequivalence window is tight, but you should monitor for any subjective differences.
Is the generic less effective? No. By regulatory definition, a generic must be bioequivalent, meaning no clinically meaningful difference in efficacy or safety.
Will insurance pay less for the generic? Usually. Most insurers negotiate lower copays for generics.

6. Bottom Line Summary

  • Brand: Ivadien (also Vyndaqel in the EU).
  • Generic: Available in the EU, Canada, Australia, and many other regions; not yet approved in the U.S.
  • When it becomes available in the U.S., you can expect a significant price reduction compared to the brand name.

If you need more specific information about generic availability in a particular country, let me know the country and I can dig into the local regulatory database for you!



Other Questions About Tafamidis :

Tafamidis? Tafamidis patent? Pfizer tafamidis patent? Tafamidis generic name? Tafamidis patent expiration date? Tafamidis generic availability united states 2025? Tafamidis patent expiry?